Filing search / VBI Vaccines Inc / "Mission"

8-K

EX-99.1

VBIVQ VBI Vaccines Inc

14 Feb 24

VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences

8:34am

, and public health, and we believe this deal better positions us to deliver on this mission.” The proceeds from these agreements will be used

8-K

EX-99.1

VBIVQ VBI Vaccines Inc

4 Apr 23

VBI Vaccines Announces Increased Focus on Hepatitis B, Organizational Changes, and Reverse Stock Split

8:00am

to our mission and for their contributions to VBI’s progress to date.” About the Organizational Changes As part of this commitment, the company

8-K

EX-99.1

VBIVQ VBI Vaccines Inc

6 Dec 22

Entry into a Material Definitive Agreement

9:25am

, and civil organizations, launched in 2017, to develop vaccines against future epidemics. Its mission is to accelerate the development of vaccines … , globally accessible vaccines against new threats to just 100 days. Achieving this ‘100 Days Mission’ would give the world a fighting chance of containing

8-K

EX-99.1

VBIVQ VBI Vaccines Inc

15 Sep 22

VBI Vaccines Secures $100 Million Debt Facility From K2 HealthVentures

5:01pm

commercialization and pipeline development efforts, and we look forward to continuing to work with the VBI team in their mission to address significant

8-K

EX-99.1

VBIVQ VBI Vaccines Inc

8 Sep 22

Regulation FD Disclosure

6:10am

to this differentiated 3-antigen HBV vaccine in Europe. Strategically, VBI and Valneva are two companies aligned by a shared mission to reduce the burden

8-K

EX-99.1

tmsljal3zjr6 nkyac

9 May 22

VBI Vaccines Reports First Quarter 2022 Financial Results and Provides Corporate Update

8:00am

8-K

EX-99.1

vly110dl7rejq80ig

1 Dec 21

VBI Vaccines Announces FDA Approval of PreHevbrio™ for the Prevention of Hepatitis B in Adults

7:30am

8-K

ls8e3yxuyp0tai

10 Mar 21

VBI Vaccines Announces Initiation of Enrollment in Adaptive Phase 1/2 Study of Prophylactic COVID-19 Vaccine Candidate, VBI-2902

7:38am

8-K

EX-99.2

0f7jooz

10 Mar 21

VBI Vaccines Announces Initiation of Enrollment in Adaptive Phase 1/2 Study of Prophylactic COVID-19 Vaccine Candidate, VBI-2902

7:38am

8-K

EX-99.1

zc8ocykmhsy7ezpqte

2 Mar 21

VBI Vaccines Reports Fourth Quarter and Full Year Financial Results for 2020, Provides Corporate Update and Outlook for 2021

8:00am

8-K

EX-99.1

jfdgx5wo

7 Dec 20

VBI Vaccines Selects Syneos Health as Commercialization Partner for Prophylactic 3-Antigen Hepatitis B Vaccine

10:23am

8-K

EX-99.1

3dyvp

2 Nov 20

VBI Vaccines Announces Third Quarter 2020 Financial Results and Provides Corporate Update

11:31am

8-K

EX-99.1

7a9rqvxgwcmjv9ap

6 Dec 18

VBI Vaccines Enters into License and Collaboration Agreement

8:05am